Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) EBIT Margin (2017 - 2025)

Sutro Biopharma's EBIT Margin history spans 9 years, with the latest figure at 499.94% for Q3 2025.

  • For Q3 2025, EBIT Margin rose 29723.0% year-over-year to 499.94%; the TTM value through Sep 2025 reached 175.66%, down 9069.0%, while the annual FY2024 figure was 384.34%, 32626.0% down from the prior year.
  • EBIT Margin for Q3 2025 was 499.94% at Sutro Biopharma, down from 4.43% in the prior quarter.
  • Across five years, EBIT Margin topped out at 37.95% in Q4 2023 and bottomed at 1202.0% in Q1 2025.
  • The 5-year median for EBIT Margin is 333.26% (2023), against an average of 365.23%.
  • The largest annual shift saw EBIT Margin surged 60817bps in 2023 before it crashed -76695bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 328.85% in 2021, then crashed by -73bps to 570.23% in 2022, then soared by 107bps to 37.95% in 2023, then crashed by -1261bps to 440.66% in 2024, then fell by -13bps to 499.94% in 2025.
  • Per Business Quant, the three most recent readings for STRO's EBIT Margin are 499.94% (Q3 2025), 4.43% (Q2 2025), and 1202.0% (Q1 2025).